Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -25.25% is 50% above its 5-year average of -50.43%, near the high end of its 5-year range (-202.22%–-19.88%).
As of the fiscal period ended Tuesday, June 30, 2026. 40.41% above its 12-month average of -42.37%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -25.25%.
RETURN ON INVESTED CAPITAL (ROIC)
-25.25%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-42.37%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-53.59%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-50.43%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-50.00%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+40.41%
CURRENT VS 3Y AVG
+52.88%
CURRENT VS 5Y AVG
+49.93%
CURRENT VS 10Y AVG
+49.50%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.43%
median of 499 covered companies
CURRENT VS SECTOR MEDIAN
+11.19%
vs the sector median at left
Corvus Pharmaceuticals, Inc.
Market Cap
$892.20M
Return on Invested Capital (ROIC)
-25.25%
TTM Avg
-42.37%
3Y Avg
-53.59%
5Y Avg
-50.43%
Market Cap
$916.63M
Return on Invested Capital (ROIC)
11.37%
TTM Avg
4.29%
3Y Avg
-4.73%
5Y Avg
-2.12%
Market Cap
$917.68M
Return on Invested Capital (ROIC)
4.96%
TTM Avg
4.19%
3Y Avg
3.59%
5Y Avg
3.20%
Market Cap
$892.87M
Return on Invested Capital (ROIC)
54.39%
TTM Avg
-47.91%
3Y Avg
-50.01%
5Y Avg
-47.22%
Market Cap
$851.97M
Return on Invested Capital (ROIC)
-28.69%
TTM Avg
-21.44%
3Y Avg
-33.52%
5Y Avg
-49.04%
Market Cap
$864.96M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$853.35M
Return on Invested Capital (ROIC)
-37.39%
TTM Avg
-65.53%
3Y Avg
-61.64%
5Y Avg
-93.68%
Market Cap
$949.71M
Return on Invested Capital (ROIC)
-46.54%
TTM Avg
-25.88%
3Y Avg
-39.60%
5Y Avg
-39.60%
Market Cap
$940.12M
Return on Invested Capital (ROIC)
-67.13%
TTM Avg
-38.55%
3Y Avg
-37.38%
5Y Avg
-31.65%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | $892.20M | -25.25% | -42.37% | -53.59% | -50.43% |
| Bioventus Inc. (BVS)vs › | $916.63M | 11.37% | 4.29% | -4.73% | -2.12% |
| HealthStream, Inc. (HSTM)vs › | $917.68M | 4.96% | 4.19% | 3.59% | 3.20% |
| Arbutus Biopharma Corp (ABUS)vs › | $892.87M | 54.39% | -47.91% | -50.01% | -47.22% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $851.97M | -28.69% | -21.44% | -33.52% | -49.04% |
| Apnimed, Inc. (APMD)vs › | $864.96M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $853.35M | -37.39% | -65.53% | -61.64% | -93.68% |
| CeriBell, Inc. (CBLL)vs › | $949.71M | -46.54% | -25.88% | -39.60% | -39.60% |
| Kura Oncology, Inc. (KURA)vs › | $940.12M | -67.13% | -38.55% | -37.38% | -31.65% |
| Beta Bionics, Inc. (BBNX)vs › | $866.05M | -31.17% | -29.64% | -85.48% | -85.48% |
ROIC
-25.2%
ROE
-24.0%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -25.25% |
| 2026-03-31 | -19.88% |
| 2025-12-31 | -69.15% |
| 2025-09-30 | -53.67% |
| 2025-06-30 | -43.90% |
| 2025-03-31 | -62.24% |
| 2024-12-31 | -82.22% |
| 2024-09-30 | -202.22% |
| 2024-06-30 | -45.68% |
| 2024-03-31 | -69.19% |
| 2023-12-31 | -60.51% |
| 2023-09-30 | -52.47% |
| 2023-06-30 | -58.92% |
| 2023-03-31 | -63.57% |
| 2022-12-31 | -56.65% |
| 2022-09-30 | -49.90% |
| 2022-06-30 | -36.76% |
| 2022-03-31 | -37.56% |
| 2021-12-31 | -38.72% |
| 2021-09-30 | -38.60% |
| 2021-06-30 | -43.80% |
| 2021-03-31 | -43.53% |
| 2020-12-31 | -59.63% |
| 2020-09-30 | -100.97% |
| 2020-06-30 | -89.29% |
| 2020-03-31 | -80.24% |
| 2019-12-31 | -65.75% |
| 2019-09-30 | -57.98% |
| 2019-06-30 | -52.18% |
| 2019-03-31 | -45.22% |
| 2018-12-31 | -44.61% |
| 2018-09-30 | -42.05% |
| 2018-06-30 | -40.61% |
| 2018-03-31 | -39.80% |
| 2017-12-31 | -66.63% |
| 2017-09-30 | -58.63% |
| 2017-06-30 | -50.13% |
| 2017-03-31 | -39.13% |
| 2016-12-31 | -27.84% |
| 2016-09-30 | -22.08% |
| 2016-06-30 | -15.96% |
| 2016-03-31 | -11.69% |
| 2015-12-31 | -14.44% |
| 2015-09-30 | -7.76% |
